<p>根据公司在最近向美国证券交易委员会（SEC）提交的文件，Generali Asset Management SPA SGR 在第三季度将其在礼来公司（NYSE:LLY - 免费报告）的持股减少了 9.5%。该基金在季度内出售了 6,430 股后，持有 61,292 股该公司的股票。礼来公司占 Generali Asset Management SPA SGR 投资组合的 1.0%，是其第 18 大持股。截至最近的 SEC 文件，Generali Asset Management SPA SGR 在礼来公司的持股价值为 46,766,000 美元。</p>
<p>获取 <strong>礼来公司</strong> 的提醒：</p>
<ul>
<li>MarketBeat 周报 – 12/29 - 01/02</li>
</ul>
<p>其他对冲基金和机构投资者也对该公司的持仓进行了调整。Braun Bostich &amp; Associates Inc.在第二季度将其在礼来公司的股份增加了 2.5%。Braun Bostich &amp; Associates Inc.现在持有 527 股该公司的股票，价值 411,000 美元，在上个季度又购买了 13 股。Rise Advisors LLC 在第二季度将其在礼来公司的股份提升了 1.8%。Rise Advisors LLC 现在持有 732 股该公司的股票，价值 571,000 美元，在上个季度又购买了 13 股。Occidental Asset Management LLC 在第二季度将其在礼来公司的股份增加了 0.7%。Occidental Asset Management LLC 现在持有 1,966 股该公司的股票，价值 1,533,000 美元，在上个季度又购买了 13 股。New Insight Wealth Advisors 在第二季度将其在礼来公司的股份增加了 3.4%。New Insight Wealth Advisors 现在持有 394 股该公司的股票，价值 307,000 美元，在上个季度又购买了 13 股。最后，Dash Acquisitions Inc.在第二季度将其在礼来公司的股份增加了 2.8%。Dash Acquisitions Inc.现在持有 485 股该公司的股票，价值 387,000 美元，在上个季度又收购了 13 股。机构投资者和对冲基金持有该公司 82.53% 的股票。</p>
<h2>分析师设定新目标价</h2>
<p>LLY 已经成为几份研究分析师报告的主题。Berenberg Bank 在 12 月 2 日的研究报告中将礼来公司的目标价从 830.00 美元上调至 950.00 美元，并给予该公司 “持有” 评级。中金公司研究在 11 月 13 日的研究报告中将礼来公司的目标价从 801.00 美元上调至 1,060.00 美元，并给予该公司 “中性” 评级。Weiss Ratings 在 12 月 22 日的研究报告中重申了对礼来公司的 “买入（b-）” 评级。Wolfe Research 在 12 月 3 日的研究报告中将礼来公司的目标价从 1,050.00 美元上调至 1,250.00 美元，并给予该公司 “跑赢大盘” 评级。最后，富国银行在 12 月 10 日的报告中将礼来公司的目标价从 1,100.00 美元上调至 1,200.00 美元，并给予该公司 “增持” 评级。五位股票研究分析师给予该股 “强烈买入” 评级，十七位给予 “买入” 评级，五位给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司的当前共识评级为 “买入”，平均目标价为 1,155.36 美元。</p>
<ul>
<li>FDA 批准诺和诺德的 Wegovy 药丸：2026 年的游戏规则改变者</li>
</ul>
<p><strong>阅读我们关于礼来公司的最新报告</strong></p>
<h2>礼来公司股票上涨 0.5%</h2>
<p>礼来公司股票在周五开盘价为 1,079.83 美元。该公司的 50 日移动平均价格为 1,013.16 美元，200 日移动平均价格为 850.41 美元。该公司的速动比率为 1.24，流动比率为 1.55，债务与股本比率为 1.71。该公司的市值为 1.02 万亿美元，市盈率为 52.83，市盈增长比率为 0.77，贝塔值为 0.35。礼来公司的 52 周低点为 623.78 美元，52 周高点为 1,111.99 美元。</p>
<ul>
<li>为什么华尔街放弃了辉瑞——这可能是个错误</li>
</ul>
<p>礼来公司（NYSE:LLY - 获取免费报告）最后一次公布财报是在 10 月 30 日，报告显示该公司季度每股收益为 7.02 美元，超出市场共识预期的 6.42 美元，超出幅度为 0.60 美元。该公司季度收入为 176 亿美元，而市场共识预期为 160.9 亿美元。礼来公司的股本回报率为 109.52%，净利润率为 30.99%。该公司的收入同比增长 53.9%。去年同期，该公司每股收益为 1.18 美元。礼来公司已将其 2025 财年的指导目标设定为 23.000-23.700 每股收益。整体来看，研究分析师预计礼来公司今年将发布 23.48 每股收益。</p>
<h2>礼来公司增加股息</h2>
<p>该公司最近还披露了季度股息，将于 3 月 10 日支付。2023 年 2 月 13 日的股东将获得 1.73 美元的股息。该股息的除息日期为 2023 年 2 月 13 日。这代表着每年 6.92 美元的股息，收益率为 0.6%。这比礼来公司之前的季度股息 1.50 美元有所增加。礼来公司的股息支付比率目前为 29.35%。</p>
<h2>礼来公司公司简介</h2>
<p>（免费报告）</p>
<p>礼来公司 NYSE: LLY 是一家成立于 1876 年的全球制药公司，总部位于印第安纳州印第安纳波利斯。该公司研究、开发、生产和商业化广泛的药物和疗法，服务于全球患者。礼来公司在北美、欧洲、亚洲及其他地区开展业务并拥有商业存在，服务于发达市场和新兴市场。近年来，该公司由总裁兼首席执行官 David A.领导。</p>
<h2>特色文章</h2>
<ul>
<li>我们更看好的五只股票，胜过礼来公司</li>
<li>请勿删除，立即阅读</li>
<li>没有人告诉你的 100 万亿的人工智能故事</li>
<li>如果你在美国银行账户中存有现金……请立即阅读</li>
<li>华尔街股票挑选者评选 2026 年第一股票</li>
<li>但在 2026 年 5 月 20 日之前，这只 2 美元的黄金股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在礼来公司吗？</h2>
<p>在考虑礼来公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而礼来公司并不在名单上。</p>
<p>虽然礼来公司目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

礼来

<p>Generali Asset Management SPA SGR 在第三季度减少了对礼来的持股，降幅为 9.5%，目前持有 61,292 股，估值约为 4677 万美元。这只股票占其投资组合的 1.0%。其他机构投资者也调整了他们的持仓，多个公司增加了他们的股份。分析师为礼来设定了新的价格目标，普遍评级为 “买入”，平均目标价格为 1,155.36 美元。该股票开盘价为 1,079.83 美元，略微上涨 0.5%</p>

<p>Generali Asset Management SPA SGR lowered its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 9.5% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 61,292 shares of the company's stock after selling 6,430 shares during the quarter. Eli Lilly and Company comprises 1.0% of Generali Asset Management SPA SGR's investment portfolio, making the stock its 18th biggest holding. Generali Asset Management SPA SGR's holdings in Eli Lilly and Company were worth $46,766,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>根据公司在最近向美国证券交易委员会（SEC）提交的文件，Generali Asset Management SPA SGR 在第三季度将其在礼来公司（NYSE:LLY - 免费报告）的持股减少了 9.5%。该基金在季度内出售了 6,430 股后，持有 61,292 股该公司的股票。礼来公司占 Generali Asset Management SPA SGR 投资组合的 1.0%，是其第 18 大持股。截至最近的 SEC 文件，Generali Asset Management SPA SGR 在礼来公司的持股价值为 46,766,000 美元。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>礼来公司</strong> 的提醒：</p>
</div><ul>
<li>MarketBeat Week in Review – 12/29 - 01/02</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周报 – 12/29 - 01/02</li>
</ul>
</div><p>Other hedge funds and other institutional investors have also made changes to their positions in the company. Braun Bostich &amp; Associates Inc. increased its stake in Eli Lilly and Company by 2.5% in the second quarter. Braun Bostich &amp; Associates Inc. now owns 527 shares of the company's stock valued at $411,000 after purchasing an additional 13 shares during the last quarter. Rise Advisors LLC lifted its position in shares of Eli Lilly and Company by 1.8% during the 2nd quarter. Rise Advisors LLC now owns 732 shares of the company's stock worth $571,000 after buying an additional 13 shares during the last quarter. Occidental Asset Management LLC boosted its holdings in shares of Eli Lilly and Company by 0.7% in the 2nd quarter. Occidental Asset Management LLC now owns 1,966 shares of the company's stock valued at $1,533,000 after buying an additional 13 shares in the last quarter. New Insight Wealth Advisors grew its position in shares of Eli Lilly and Company by 3.4% in the 2nd quarter. New Insight Wealth Advisors now owns 394 shares of the company's stock valued at $307,000 after buying an additional 13 shares during the last quarter. Finally, Dash Acquisitions Inc. raised its stake in Eli Lilly and Company by 2.8% during the 2nd quarter. Dash Acquisitions Inc. now owns 485 shares of the company's stock worth $387,000 after acquiring an additional 13 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.</p>
<div class="lb-trans"><p>其他对冲基金和机构投资者也对该公司的持仓进行了调整。Braun Bostich &amp; Associates Inc.在第二季度将其在礼来公司的股份增加了 2.5%。Braun Bostich &amp; Associates Inc.现在持有 527 股该公司的股票，价值 411,000 美元，在上个季度又购买了 13 股。Rise Advisors LLC 在第二季度将其在礼来公司的股份提升了 1.8%。Rise Advisors LLC 现在持有 732 股该公司的股票，价值 571,000 美元，在上个季度又购买了 13 股。Occidental Asset Management LLC 在第二季度将其在礼来公司的股份增加了 0.7%。Occidental Asset Management LLC 现在持有 1,966 股该公司的股票，价值 1,533,000 美元，在上个季度又购买了 13 股。New Insight Wealth Advisors 在第二季度将其在礼来公司的股份增加了 3.4%。New Insight Wealth Advisors 现在持有 394 股该公司的股票，价值 307,000 美元，在上个季度又购买了 13 股。最后，Dash Acquisitions Inc.在第二季度将其在礼来公司的股份增加了 2.8%。Dash Acquisitions Inc.现在持有 485 股该公司的股票，价值 387,000 美元，在上个季度又收购了 13 股。机构投资者和对冲基金持有该公司 82.53% 的股票。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>LLY has been the subject of several research analyst reports. Berenberg Bank upped their price objective on shares of Eli Lilly and Company from $830.00 to $950.00 and gave the company a &#34;hold&#34; rating in a research note on Tuesday, December 2nd. CICC Research upped their target price on Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a &#34;neutral&#34; rating in a research report on Thursday, November 13th. Weiss Ratings restated a &#34;buy (b-)&#34; rating on shares of Eli Lilly and Company in a research note on Monday, December 22nd. Wolfe Research boosted their price objective on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an &#34;outperform&#34; rating in a research note on Wednesday, December 3rd. Finally, Wells Fargo &amp; Company increased their price objective on Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the company an &#34;overweight&#34; rating in a report on Wednesday, December 10th. Five equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of &#34;Buy&#34; and an average target price of $1,155.36.</p>
<div class="lb-trans"><p>LLY 已经成为几份研究分析师报告的主题。Berenberg Bank 在 12 月 2 日的研究报告中将礼来公司的目标价从 830.00 美元上调至 950.00 美元，并给予该公司 “持有” 评级。中金公司研究在 11 月 13 日的研究报告中将礼来公司的目标价从 801.00 美元上调至 1,060.00 美元，并给予该公司 “中性” 评级。Weiss Ratings 在 12 月 22 日的研究报告中重申了对礼来公司的 “买入（b-）” 评级。Wolfe Research 在 12 月 3 日的研究报告中将礼来公司的目标价从 1,050.00 美元上调至 1,250.00 美元，并给予该公司 “跑赢大盘” 评级。最后，富国银行在 12 月 10 日的报告中将礼来公司的目标价从 1,100.00 美元上调至 1,200.00 美元，并给予该公司 “增持” 评级。五位股票研究分析师给予该股 “强烈买入” 评级，十七位给予 “买入” 评级，五位给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司的当前共识评级为 “买入”，平均目标价为 1,155.36 美元。</p>
</div><ul>
<li>FDA Approves Novo Nordisk's Wegovy Pill: A Game Changer for 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>FDA 批准诺和诺德的 Wegovy 药丸：2026 年的游戏规则改变者</li>
</ul>
</div><p><strong>Read Our Latest Report on Eli Lilly and Company</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于礼来公司的最新报告</strong></p>
</div><h2>Eli Lilly and Company Stock Up 0.5%</h2>
<div class="lb-trans"><h2>礼来公司股票上涨 0.5%</h2>
</div><p>LLY opened at $1,079.83 on Friday. The business has a 50 day moving average price of $1,013.16 and a two-hundred day moving average price of $850.41. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The company has a market cap of $1.02 trillion, a PE ratio of 52.83, a P/E/G ratio of 0.77 and a beta of 0.35. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,111.99.</p>
<div class="lb-trans"><p>礼来公司股票在周五开盘价为 1,079.83 美元。该公司的 50 日移动平均价格为 1,013.16 美元，200 日移动平均价格为 850.41 美元。该公司的速动比率为 1.24，流动比率为 1.55，债务与股本比率为 1.71。该公司的市值为 1.02 万亿美元，市盈率为 52.83，市盈增长比率为 0.77，贝塔值为 0.35。礼来公司的 52 周低点为 623.78 美元，52 周高点为 1,111.99 美元。</p>
</div><ul>
<li>Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么华尔街放弃了辉瑞——这可能是个错误</li>
</ul>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company's revenue was up 53.9% on a year-over-year basis. During the same period last year, the business posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY - 获取免费报告）最后一次公布财报是在 10 月 30 日，报告显示该公司季度每股收益为 7.02 美元，超出市场共识预期的 6.42 美元，超出幅度为 0.60 美元。该公司季度收入为 176 亿美元，而市场共识预期为 160.9 亿美元。礼来公司的股本回报率为 109.52%，净利润率为 30.99%。该公司的收入同比增长 53.9%。去年同期，该公司每股收益为 1.18 美元。礼来公司已将其 2025 财年的指导目标设定为 23.000-23.700 每股收益。整体来看，研究分析师预计礼来公司今年将发布 23.48 每股收益。</p>
</div><h2>Eli Lilly and Company Increases Dividend</h2>
<div class="lb-trans"><h2>礼来公司增加股息</h2>
</div><p>The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 annualized dividend and a yield of 0.6%. This is an increase from Eli Lilly and Company's previous quarterly dividend of $1.50. Eli Lilly and Company's dividend payout ratio is presently 29.35%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度股息，将于 3 月 10 日支付。2023 年 2 月 13 日的股东将获得 1.73 美元的股息。该股息的除息日期为 2023 年 2 月 13 日。这代表着每年 6.92 美元的股息，收益率为 0.6%。这比礼来公司之前的季度股息 1.50 美元有所增加。礼来公司的股息支付比率目前为 29.35%。</p>
</div><h2>Eli Lilly and Company Company Profile</h2>
<div class="lb-trans"><h2>礼来公司公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.</p>
<div class="lb-trans"><p>礼来公司 NYSE: LLY 是一家成立于 1876 年的全球制药公司，总部位于印第安纳州印第安纳波利斯。该公司研究、开发、生产和商业化广泛的药物和疗法，服务于全球患者。礼来公司在北美、欧洲、亚洲及其他地区开展业务并拥有商业存在，服务于发达市场和新兴市场。近年来，该公司由总裁兼首席执行官 David A.领导。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>Do not delete, read immediately</li>
<li>The $100 Trillion AI Story No One Is Telling You</li>
<li>If You Keep Cash In A U.S. Bank Account… Read This NOW</li>
<li>Wall Street Stockpicker Names #1 Stock of 2026</li>
<li>But this $2 Gold Stock Before May 20, 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过礼来公司</li>
<li>请勿删除，立即阅读</li>
<li>没有人告诉你的 100 万亿的人工智能故事</li>
<li>如果你在美国银行账户中存有现金……请立即阅读</li>
<li>华尔街股票挑选者评选 2026 年第一股票</li>
<li>但在 2026 年 5 月 20 日之前，这只 2 美元的黄金股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在礼来公司吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑礼来公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而礼来公司并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然礼来公司目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

忠利资产管理公司 SPA SGR 减少了其在礼来公司 $LLY 的持股